Press release
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
Company-Sponsored Industry Symposium To Be Held at the ERS Congress LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical
About this update from Savara, Inc.
[{"type":"text","content":"\nCompany-Sponsored Industry Symposium To Be Held at the ERS Congress\n\n\n LANGHORNE, Pa.--(BUSINESS WIRE)--\nSavara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an abstract for poster presentation at the European Respiratory Society (ERS) Congress 2024, taking place September 7-11, 2024, in Vienna, Austria. The Company is also sponsoring an Industry Symposium at the Congress. Details are as follows:\n\n\nAccepted Abstract\nTitle: “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life (HRQoL) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from IMPALA-2”\nPoster Session PS-29: Deep in Clinical Dilemmas of Non-Idiopathic Interstitial Lung Diseases\nDate and Time: September 8, 2024, 12:30-14:00 CET\n\n\nCompany-Sponsored Symposium\nTitle: “Pulmonary Alveolar Proteinosis: Pathophysiology, Diagnosis, and Management”\nLocation: ERS Congress Industry Theater\nDate and Time: September 8, 2024, 17:30 – 19:00 CET\nSpeakers: Cormac McCarthy, M.D., Ph.D., FRCPI, Elisabeth Bendstrup, M.D., Ph.D., and Francesco Bonella, M.D., Ph.D.\n\n\nAbout aPAP\n\n\nAutoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli (or air sacs) of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the inside of the alveoli to prevent the alveoli from collapsing. In a healthy lung, the old and inactivated surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering the macrophages unable to adequately clear surfactant. The resulting excess surfactant accumulates in the alveoli, creating a barrier to gas exchange, and manifesting clinically as shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long-term, the disease can lead to serious complications, including lung fibrosis and the need for a ...